Journal Reading

and efficacy of cardiac ESWT in the patients with concomitant EnD-CAD and
ESRD.This journal was prospective study between August 2016 and January 2019.
The result of this journal All participants tolerated cardiac ESWT without any
relevant side effects such as skin allergic reaction, local redness/tenderness or cardiac
arrhythmia. There were similar baseline comorbidities and clinical features between
two groups, but the EnD-CAD/ESRD group had significantly higher serum potassium
level as well as lower renal function and lipid profile (all p-values <0.03). After
cardiac ESWT, the patients in both groups had significant improvement in angina and
dyspnea at 1 year (all p-values <0.03). However, the EnD-CAD/ESRD group did not
have increase in either circulating EPC levels or LVEF at 6 months (p 1.000). In
contrast, the EnD-CAD group had gradually improving levels of circulating EPC
surface markers and increased LV systolic function (p 0.092). Notably, patients in the
EnD-CAD/ESRD group suffered from high incidental clinical adverse events before
and after enrollment into the ESWT study (p 0.132).
The conclusion of this journal is although cardiac ESWT provided
mprovement of clinical symptoms in the EnD-CAD patients, its long-term effects on
the angiogenesis and LVEF were reduced for those high-risk patients with
concomitant EnD-CAD and ESRD.